Rollakanti Kishore R, Kanick Stephen C, Davis Scott C, Pogue Brian W, Maytin Edward V
Department of Chemical and Biomedical Engineering, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA; and Department of Biomedical Engineering, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Thayer School of Engineering, Dartmouth College, 14 Engineering Drive, Hanover, NH 03755, USA.
Photonics Lasers Med. 2013 Nov 1;2(4):287-303. doi: 10.1515/plm-2013-0030.
Photodynamic therapy (PDT) is a treatment modality that uses a specific photosensitizing agent, molecular oxygen, and light of a particular wavelength to kill cells targeted by the therapy. Topically administered aminolevulinic acid (ALA) is widely used to effectively treat cancerous and precancerous skin lesions, resulting in targeted tissue damage and little to no scarring. The targeting aspect of the treatment arises from the fact that ALA is preferentially converted into protoporphyrin IX (PpIX) in neoplastic cells. To monitor the amount of PpIX in tissues, techniques have been developed to measure PpIX-specific fluorescence, which provides information useful for monitoring the abundance and location of the photosensitizer before and during the illumination phase of PDT. This review summarizes the current state of these fluorescence detection techniques. Non-invasive devices are available for point measurements, or for wide-field optical imaging, to enable monitoring of PpIX in superficial tissues. To gain access to information at greater tissue depths, multi-modal techniques are being developed which combine fluorescent measurements with ultrasound or optical coherence tomography, or with microscopic techniques such as confocal or multiphoton approaches. The tools available at present, and newer devices under development, offer the promise of better enabling clinicians to inform and guide PDT treatment planning, thereby optimizing therapeutic outcomes for patients.
光动力疗法(PDT)是一种治疗方式,它使用特定的光敏剂、分子氧和特定波长的光来杀死该疗法所针对的细胞。局部施用的氨基乙酰丙酸(ALA)被广泛用于有效治疗癌性和癌前皮肤病变,可导致靶向组织损伤且几乎不会留下疤痕。该治疗的靶向性源于这样一个事实,即ALA在肿瘤细胞中优先转化为原卟啉IX(PpIX)。为了监测组织中PpIX的含量,已开发出测量PpIX特异性荧光的技术,该技术可提供在PDT光照阶段之前和期间监测光敏剂丰度和位置的有用信息。本综述总结了这些荧光检测技术的现状。有非侵入性设备可用于单点测量或宽视野光学成像,以监测浅表组织中的PpIX。为了获取更深组织深度的信息,正在开发多模态技术,这些技术将荧光测量与超声或光学相干断层扫描相结合,或与共聚焦或多光子等显微技术相结合。目前可用的工具以及正在开发的更新设备有望更好地使临床医生为PDT治疗计划提供信息并进行指导,从而为患者优化治疗效果。